# Anaptysbio, Inc. (ANAB)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001370053 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001370053))
- Full page: https://inspectstocks.com/stocks/anab
- Data as of: price 2026-09-28; newest filing used 2026-09-21; latest fiscal period ended 2026-06-30

## Grade

**B+** on the growth-and-cash rubric, 4 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $237.6M | $12.9M |
| Revenue growing recently | passed | $237.6M | $234.6M |
| Free cash flow positive | passed | $4.4M |  |
| Free cash flow growing overall | passed | $4.4M | -$77.6M |
| Free cash flow growing recently | failed | $4.4M | $19.6M |

Business quality (the + / − mark): 5 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 82.4% |  |
| Healthy profit margin | passed | 82.4% |  |
| Strong operating margin | passed | 131.7% |  |
| Good return on equity | passed | 526.0% |  |
| Debt under control | passed | 0.38 |  |
| Turns sales into cash | failed | 1.9% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $237.6M |
| Net income, trailing twelve months | $195.7M |
| Free cash flow, trailing twelve months | $4.4M |
| Net margin | 82.4% |
| Operating margin | 131.7% |
| Return on equity | 526.0% |
| Debt to equity | 0.38 |
| Diluted EPS, trailing twelve months | $5.74 |
| Share price | $50.82 |
| Market value | $1.5B |
| Price / earnings | 8.9x |
| Price / sales | 6.4x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/anab)
- [Financial statements](https://inspectstocks.com/stocks/anab/financials)
- [Competitors](https://inspectstocks.com/stocks/anab/peers)
- [Earnings](https://inspectstocks.com/stocks/anab/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.